Skip to main content

Citius Oncology, Inc.

CTOR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001851484

No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Citius Oncology, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of CTOR: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders716+9
Shares227.5K8.36M+8.13M (+3,573.6%)
Value$989.6K$17.0M+$16.0M (+1,614.5%)

New holders (10)

Institutions that held Citius Oncology, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to CTOR in Q3 2025
InstitutionSharesValue% of portfolio
Armistice Capital, LLC7,675,911$15.6M0.49%
Vanguard Group Inc180,168$365.7K0.00%
XTX Topco Ltd126,884$257.6K0.01%
Renaissance Technologies LLC55,900$113.5K0.00%
State Street Corp42,900$87.1K0.00%
Northern Trust Corp21,764$44.2K0.00%
Citadel Advisors LLC17,661$35.9K0.00%
Tower Research Capital LLC (TRC)11,846$24.0K0.00%
Morgan Stanley5$100.00%
Farther Finance Advisors, LLC3$60.00%

Sold out (1)

Institutions that held Citius Oncology, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of CTOR in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Jane Street Group, LLC106,970$465.3K